Blog

Svetlana Nikic: Consistent Theme that Emerges Around the Clinical and Economic Value of Circulating Tumor DNA

Svetlana Nikic/precision-oncology-consulting.com

Jul 31, 2025, 23:28

Svetlana Nikic: Consistent Theme that Emerges Around the Clinical and Economic Value of Circulating Tumor DNA

Svetlana Nikic, Founder of Precision Oncology Consulting, shared a post on LinkedIn:

“Here are 8 posters from latest ESMOGI25 where a consistent theme emerges around the clinical and economic value of circulating tumor DNA (ctDNA) in colorectal and esophageal cancers.

Multiple studies demonstrated that ctDNA positivity post-treatment is a strong predictor of recurrence, with technologies like tissue-free Latitude by Natera, methylation-based assays such as Guardant Reveal by Guardant Health and newer assays such as Oncodetect v2 by Exact Sciences and @xM by Tempus AI are showing high sensitivity and specificity for minimal residual disease (MRD) detection.

Additionally, economic analyses from both UK and Italian perspectives highlighted that ctDNA-guided strategies can reduce unnecessary treatments and healthcare costs, reinforcing their cost-effectiveness and clinical utility in both stage II and III colorectal cancer settings.

Natera presented a diverse MRD portfolio, including both tumor-informed and tissue-free assays, with strong clinical and economic value.
Exact Sciences demonstrated technical innovation, pushing MRD detection from binary to quantitative and genome-wide resolution.
Guardant Health emphasized the practicality and scalability of tissue-free MRD testing in diverse global populations.
Tempus AI showed how longitudinal ctDNA monitoring can guide prognosis and recurrence surveillance.

Let me know if you find this insightful and if so, please share.”

More posts featuring Svetlana Nikic.